tbuckley/cabot-search huggingface dataset:
Coexistence of an imbalance of cytokines, chemokines and growth factors serum levels and symptoms of fatigue and pain in long-term breast cancer survivors.
Authors: Antonella Daniele, Rosa Divella, Ines Abbate, Francesco Giotta, Pierpaolo Trerotoli, Alessandro Mautino, Porzia Casamassima, Angelo Paradiso, Francesca Romito, Claudia Cormio, Maria Domenica Carbonara, Rosanna Mallamaci, Vittorio Mattioli
Journal: Journal of Clinical Oncology (2015)

e20626 Background: Fatigue, pain and depression are common problems among long-term cancer survivors (BCS) which in some patients may persist for many years after healing and the completion of treatment. Several studies have reported that increased serum levels of chemokines and growth factors are particularly significantly correlated with the coexistence of these disorders in cancer survivors. The aim of this study was to assess whether the altered imbalance of pro-inflammatory cytokines, growth factors and chemokine serum levels are associated to presence of fatigue and pain in long-term breast cancer survivors . Methods: Ninety-three BCS were enrolled in this study and blood samples taken from each. Serum levels of 25 analytes including cytokines, growth factors and chemokines were tested by enzyme immunoassay using the flexible Bio-Plex System. Participants also completed a questionnaire measuring demographic, clinical and behavioral variables. Results: Non-parametric discriminant analysis showed that fatigued BCS had significantly higher serum levels of FGF and lower IL-4 and IL-8 compared to the non-fatigued group, while BCS with pain had an increase in eotaxin serum levels and lower IL-4 and Il-7 compared to the group without pain. Univariate analysis showed a statistically significant difference in both mental and physical qol, with levels lower in the subgroup who presented pain than in those without: p = 0.0003 and p < 0.0001 respectively. A lower value of Rantes (p = 0.0131) in breast cancer survivors with pain compared to the group without pain, and a higher median value of TNF-α (p = 0.054) in the pain group than in those without pain was observed. The level of depression was higher than the score of 50 on the Zung scale in fatigued survivors compared to non-fatigued survivors (p = 0.0006). Conclusions: Our results suggest that an altered balance of chemokines, cytokines and growth factors serum levels may be associated to presence of symptoms such as fatigue and pain in breast cancer survivors at an average of 5 years after diagnosis.
Asbestos disease expert wins right to obtain information held on him by lobbyist
Authors: Clare Dyer
Journal: BMJ (2019)

A leading expert on asbestos related cancers has won a landmark Data Protection Act claim at the High Court against a lobbyist who accused him of giving fraudulent evidence in court cases and tried to get him struck off the medical register.1

Robin Rudd, a consultant physician specialising in respiratory diseases and cancer, has spent 35 years giving expert evidence in cases in which claimants have sought damages for mesothelioma, lung cancer, asbestosis, and pleural disease allegedly caused by exposure to asbestos.

John Bridle, 79, has been involved for 50 years in the manufacture and use of chrysotile (white) asbestos and asbestos cement products used in building. Under the banner …
Final results of a phase II study of bevacizumab, cisplatin and pemetrexed as first-line therapy for patients with advanced non squamous non small cell lung cancer.
Authors: Guillermo Lopez Vivanco, Sergio Carrera, Itziar Rubio, Eider Azcona, Aintzane Sancho, Begona Calvo, Aitziber Buque, Unai Aresti
Journal: Journal of Clinical Oncology (2015)

e19036 Background: Both pemetrexed-cisplatin and bevacizumab-based therapy are treatment options for patients with advanced non-squamous NSCLC. The objective of this study was to explore efficacy and safety of first-line pemetrexed-cisplatin plus bevacizumab followed by maintenance bevacizumab in a sample of Spanish patients, and also study the K-Ras and VEGF status. Methods: Patients (N = 31) with previously untreated advanced non-squamous NSCLC were enrolled. PFS and OS were assessed by Kaplan-Meier curves and analyzed using the log-rank test and Cox proportional hazards model. K-RAS mutational status was determined at the beginning of the study. VEGF levels were assessed before 1st cycle and every 2 cycles thereafter until progression. Patients received bevacizumab 7.5 mg/kg, cisplatin 75 mg/m2 and pemetrexed 500 mg/ m2, given on day 1 each 21-days up to 6 cycles followed by maintenance bevacizumab. Results: By March 2012, 31 patients were enrolled. Median age was 59 years (range: 42–74); 67.7% were men and 32.3% women; ECOG status was 0 in 16.1% and 1 in 83.9%. All patients had metastatic disease (most common sites were lung: 64.5%, bone: 51.8% and liver: 41.9%). 58.06% patients were KRAS wild type, 22.58% KRAS positive, and 19.35% had an unknown result. Median PFS was 7.2 months and median OS was 11.3 months. Partial response was achieved by 48.4% of patients and a further 25.8% had stable disease (disease control rate was 74.2%). Twenty four patients (77.4%) experienced at least a grade 3-4 AE. The most common grade ≥ 3 bevacizumab-related AEs were: Hypertension 9.7%, pulmonary embolism (9.7%) and deep vein thrombosis (9.7%). Conclusions: In this trial, patients treated in first-line with pemetrexed-cisplatin plus bevacizumab shown and acceptable benefit in PFS and OS. Also good disease control rate was achieved in high percentage of patients despite a poor prognosis population (high percentage of patients with liver and bone metastases).The safety profile of the treatment was consistent with the known toxicities of each of the three agents. Clinical trial information: 2008-006145-13.
Abstract 19930: Genetically elevated NT-proBNP, Cardiovascular Outcomes and Life Expectancy in Elderly Blacks and Whites
Authors: Sara Seidelmann, Orly Vardeny, Brian Claggett, Bing Yu, Paco Bravo, Ankur Gupta, Calum MacRae, Eric Boerwinkle, Scott Solomon
Journal: Circulation (2016)

Introduction: The functional variant rs198389 in the promoter region of the B-type Natriuretic Peptide (NPPB) gene has been associated with increased gene transcription and plasma levels of NT-proBNP in whites and blacks but its relationship with cardiovascular outcomes has been understudied. Hypothesis: We hypothesize that genetic variation in the NPPB promoter region may be associated with alterations in NP response to hypertension and with cardiovascular (CV) outcomes. Methods: NT-proBNP levels were measured in 9617 black and white subjects with rs198389 genotyping who attended visit 4 of the ARIC Study. Genotype status was related to outcomes, adjusting for known predictors and confounders including age, race and BMI. Results: Overall, inheritance of the A-allele (frequency 43%) was associated with lower plasma levels of NT-proBNP compared to those with the G-allele (frequency 57%; p=1.6x10-18) as previously reported. Each 10mmHg elevation in SBP in hypertensive subjects was associated with 27% higher...
High blood platelets levels (BPL): A prognostic factor in patients with early or locally advanced non-small cell lung cancer (NSCLC)
Authors: J.F. Cordoba Ortega, A. Salud, S. Morales, J. Veas, A. Rodriguez
Journal: Annals of Oncology (2019)

Background: Patients with high blood platelets levels (BPL) have been reported to attenuate the efficacy of platinum-based chemotherapy and to have a worse prognosis when treated with surgery and postoperative adjuvant chemotherapy. This study describes a series of sample tumors from patients with clinically confirmed lung cancer. Methods: In all non-small cell lung cancer (NSCLC) patients diagnosed in the University Hospital of Lleida from January 2011 to December 2016, a real world data study of blood platelets levels (BPL) was performed. Each patient's clinical history, pathology specimens and molecular results were noted. Four hundred and forty-five patients with low BPL formed the control group. Results: The blood platelet levels (BPL) was analyzed in seven hundred and seventy-five (775) patients with an average of 290 mcL (24 - 995). In 330 patients (42%) a platelet level greater than 290 mcL was observed (22,1% females). The media age was 67 years. The smoking history was as follows: 57,2% former, 31,5% ex smokers and 11,2 never smokers. The clinical stages and histology were as follows: stage I and II: 17%, stage III: 30% and stage IV 53%; 43% of patients had adenocarcinoma histology, 36% squamous and 21% other. In patients treated with radical intention (surgery or chemotherapy plus radiotherapy) the median overall survival was 49 vs 36 months in patients with BPL ≥ 290 mcL (p = 0,00001), when they were compared with the control group, patients with high BPL (≥ 290 mcL) had overall shorter survival (p = 0,00001), regardless of histology, age or smoking history. Conclusions: Patients treated with radical intention and high BPL (≥ 290 mcL), have worse overall survival, regardless of histology, age or smoking history. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
Outbreak of Shiga toxin-producing Escherichia coli O157:H7 linked to raw drinking milk resolved by rapid application of advanced pathogen characterisation methods, England, August to October 2017
Authors: Juli Treacy, Claire Jenkins, Karthik Paranthaman, Frieda Jorgensen, Doris Mueller-Doblies, Muna Anjum, Lukeki Kaindama, Hassan Hartman, Miranda Kirchner, Therese Carson, Ishani Kar-Purkayastha
Journal: Eurosurveillance (2019)

An outbreak of Shiga toxin-producing Escherichia coli (STEC) O157:H7 occurred on the Isle of Wight between August and October 2017. Of the seven cases linked to the outbreak, five were identified through the statutory notification process and two were identified through national surveillance of whole genome sequencing data. Enhanced surveillance questionnaires established a common link to a farm, and link to the likely food vehicle, raw drinking milk (RDM). Microbiological investigations, including PCR, identified the presence of STEC O157:H7 in samples of RDM. Analysis of core genome single nucleotide polymorphism (SNP) data of STEC O157:H7 from human stool specimens, animal faecal samples and RDM demonstrated a one SNP difference between isolates, and therefore close genetic relatedness. Control measures that were put in place included suspension of sales and recall of RDM, as well as restrictions on public access to parts of the farm. Successful integration of traditional epidemiological surveillance and advanced laboratory methods for the detection and characterisation of STEC O157:H7 from human, animal and environmental samples enabled prompt identification of the outbreak vehicle and provided evidence to support the outbreak control team's decision-making, leading to implementation of effective control measures in a timely manner.
SAT-420-The value of liver stiffness to platelet ratio and liver stiffness to spleen diameter to platelet ratio score compared with hepatic venous pressure gradient to predict the portal hypertension in patients with alcoholic and viral cirrhosis
Authors: Se Ri Ryu, Seong Hee Kang, Jeong-Ju Yoo, Soung Won Jeong, Moon Young Kim, Sang Gyune Kim, Jae Young Jang, Young Seok Kim, Soon Koo Baik, Yong Jae Kim, Su Yeon Park
Journal: Journal of Hepatology (2019)
Vitamin K antagonism impairs the bone marrow microenvironment and hematopoiesis
Authors: Divij Verma, Rahul Kumar, Raquel S. Pereira, Christina Karantanou, Costanza Zanetti, Valentina R. Minciacchi, Keertik Fulzele, Kathrin Kunz, Soraya Hoelper, Sara Zia-Chahabi, Marie-Joëlle Jabagi, Joseph Emmerich, Rosemary Dray-Spira, Franziska Kuhlee, Karl Hackmann, Evelin Schroeck, Philip Wenzel, Stefan Müller, Natalie Filmann, Michaela Fontenay, Paola Divieti Pajevic, Daniela S. Krause
Journal: Blood (2019)
NF-κB hijacking theranostic Pt(ll) complex in cancer therapy
Authors: Yingzhong Zhu, Mingzhu Zhang, Lei Luo, Martin R Gill, Cesare De Pace, Giuseppe Battaglia, Qiong Zhang, Hongping Zhou, Jieying Wu, Yupeng Tian, Xiaohe Tian
Journal: Theranostics (2019)

Platinum complexes have been used for anti-cancer propose for decades, however, their high side effects resulting from damage to healthy cells cannot be neglected and prevent further clinical utilisation. Here, we designed a cyclometalated platinum (II) complex that can bind the endogenous nuclear factor-κB (NF-κB) protein. Employing detailed colocalization studies in co-culture cell line models, we show that by binding to NF-κB, the platinum (II) complex is capable of upregulated nuclear translocation specifically in cancer but not normal cells, thereby impairing cancer proliferation without disturbing healthy cells. In a murine tumour model, the platinum (II) complex prevents tumour growth to a greater extent than cisplatin and with considerably lower side-effects and kidney damage. Considering its weak damage to normal cells combined with high toxicity to cancer cells, this NF-κB-binding platinum complex is a potential anti-cancer candidate and acts to verify the strategy of hijacking endogenous trans-nuclear proteins to achieve cancer-cell specificity and enhance therapeutic indices.
<i>HLA‐B*57:01</i> confers genetic susceptibility to carbamazepine‐induced SJS/TEN in Europeans
Authors: Maja Mockenhaupt, Chuang‐Wei Wang, Shuen‐Iu Hung, Peggy Sekula, Alexander H. Schmidt, Ren‐You Pan, Chun‐Bing Chen, Ariane Dunant, Sabine Le Gouvello, Martin Schumacher, Laurence Valeyrie‐Allanore, Teresa Bellon, Sylvia H. Kardaun, Yun‐Shen Jan, Wen‐Hung Chung, Jean‐Claude Roujeau
Journal: Allergy (2019)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Abstract 20123: Impact of Cardiac Biomarkers in Patients With Stable Coronary Heart Disease on the Severity of Coronary Obstruction and Survival
Authors: Jeffrey Netto, Joachim Thiery, Ralph Burkhardt, Valentin Schlegel, Anja Willenberg, Yoon Ju Bae, Frank Beutner, Gerhard Schuler, Markus Scholz, Andrej Teren
Journal: Circulation (2017)

Introduction/Hypothesis: Cardiac biomarkers are well established diagnostic tools in patients with acute coronary syndrome and myocardial infarction. However there is only limited knowledge about t...
Employer Wellness Programs—A Work in Progress
Authors: Jean Marie Abraham
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FRI-208-Predictors of treatment response during addition of pegylated Interferon alfa-2a to an onging nucleos (t)id treatment in chronic hepatitis B: Results from the PADD-ON trial
Authors: Martin Sprinzl, Annette Grambihler, Gerlinde Teuber, Christoph Antoni, Stefan Zeuzem, Thomas Discher, Markus Cornberg, Thomas Berg, Hanns Loehr, Frank Tacke, Frank Lammert, Eckart Schott, Christoph Berg, Eugen Zizer, Renate Heyne, Ulrich Spengler, Fabian Geisler, Robert Thimme, Anita Pathil, Hartwig Klinker, Kilian Weigand, Michaela Riedl, Julia Wosniok, Jens Kittner, Marcus Schuchmann, Ulrich Alshuth, Peter Robert Galle
Journal: Journal of Hepatology (2019)
THU-197-Comparative effectiveness of 8 versus 12 weeks of ombitasvir/paritaprevir/ritonavir and dasabuvir in treatment-naive patients infected with HCV genotype 1b with non-advanced hepatic fibrosis
Authors: Dorota Zarebska-Michaluk, Jerzy Jaroszewicz, Klapaczynski Jakub, Wlodzimierz Mazur, Rafal Krygier, Teresa Belica-Wdowik, Barbara Baka-Ćwierz, Ewa Janczewska, Pawel Pabjan, Beata Dobracka, Beata Lorenc, Magdalena Tudrujek, Krzysztof Tomasiewicz, Marek Sitko, Aleksander Garlicki, Agnieszka Czauż-Andrzejuk, Jolanta Citko, Dorota Dybowska, Waldemar Halota, Małgorzata Pawłowska, Łukasz Laurans, Deron Zbigniew, Iwona Orłowska, Simon Krzysztof, Jolanta Bialkowska-Warzecha, Tronina Olga, Robert Flisiak
Journal: Journal of Hepatology (2019)
TCTAP A-086 Incidence of Irregular Protrusion Was Not Different Between Xience Drug-eluting Stent and Resolute Drug-eluting Stent
Authors: Toshimitsu Sato, Yoshiyasu Minami, Ayami Kato, Aritomo Katsura, Yusuke Muramatsu, Ryota Kakizaki, Teruyoshi Nemoto, Takuya Hashimoto, Kazuhiro Fujiyoshi, Kohki Ishida, Kentaro Meguro, Takao Shimohama, Taiki Tojo, Junya Ako
Journal: Journal of the American College of Cardiology (2019)
Diagnosis and Management of Crohn Disease
Authors: Lauren Feld, Laura R. Glick, Adam S. Cifu
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pazopanib for soft tissue sarcoma (STS) in the first- line setting with denosumab.
Authors: Hiroyuki Narahara, Kayo Yasuda, Kaori Morita, Hitoshi Matsumoto, Yuichi Yasunaga, Yoshiaki Inui, Sumio Kawata, Katsuhito Takahashi, Satoshi Teraoka
Journal: Journal of Clinical Oncology (2015)

10567 Background: We established the Japan Sarcoma Association and hold the Japan-United States International Workshop on the Sarcoma Research and Therapy in December 2014. Aim: We conducted a retrospective analysis on pazopanib for STS in order to examine the relationships of PFS with denosumab, also from the viewpoint of the first-line setting for metastatic diseases. Methods: In this study, the patients with metastatic STS treated with pazopanib from November 2012 till January 2015, consecutively, were retrospectively analyzed. Among first 4 months, the starting dose was fixed at 800mg, but later changed to 400mg because of severe adverse events. Results: Eighty seven patients (43 leiomyosarcomas, 8 liposarcomas, 36 other subtypes) were identified. Median age was 56 years old (range 17-84), 69 females and 18 males, 50 pts were treated in the first-line setting and 37 pts were in the second or later-line setting, and 26 pts with multiple bone metastases were all treated with denosumab. Remarkable severe toxicities (G 3/4) were observeded as pheumothorax, hyperbilirubinemia, bladder perforation and perianal abscess, but the rates were infrequent ( < 2.2%). All hypertension was manageable by anti-hypertensive medication and cardio-echogram showed no decrease of EF and it was definitly < 10%. But seum BNP increaseded in some pts. No pts showed symptomatic heart failure in the observation period (median: one year). All the pts, included till July 2014, were evaluable by RECIST 1.1, and 37 pts were evaluated as PR/SD and 31 pts showed PD/NE. Median OS reached 16.9 months (95%CI: 9.7-ND) and median PFS was 2.6 months (95%CI: 2.2-3.7). From the viewpoint of PFS with response, PFS in PR and that in SD were similar. PFS showed no differences between 800mg vs 400mg, leiomyosarcoma vs liposarcoma vs others, PS 0/1 vs 2/3 and 1st line vs later line. But PFS in PR/SD was longer (4.9 months, 95%CI: 2.8-7.1) than that in PD/NE (1.7 months, 95%CI: 1.1-2.3, p < 0.0001). PFS with denosumab was not inferior to that without denosumab. Conclusions: Pazopanib including first-line setting for metastatic STS is effective and comparable with EORTC trials. The combination chemotherapy of pazopanib with denosumab is promising and further investigations are warranted.
Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial
Authors: Howard M Katzenstein, Max R Langham, Marcio H Malogolowkin, Mark D Krailo, Alexander J Towbin, Mary Beth McCarville, Milton J Finegold, Sarangarajan Ranganathan, Stephen Dunn, Eugene D McGahren, Gregory M Tiao, Allison F O'Neill, Muna Qayed, Wayne L Furman, Caihong Xia, Carlos Rodriguez-Galindo, Rebecka L Meyers
Journal: The Lancet Oncology (2019)
Time of Exercise Specifies the Impact on Muscle Metabolic Pathways and Systemic Energy Homeostasis
Authors: Shogo Sato, Astrid Linde Basse, Milena Schönke, Siwei Chen, Muntaha Samad, Ali Altıntaş, Rhianna C. Laker, Emilie Dalbram, Romain Barrès, Pierre Baldi, Jonas T. Treebak, Juleen R. Zierath, Paolo Sassone-Corsi
Journal: Cell Metabolism (2019)
LBP-15-Urinary Liver Fatty-Acid-Binding Protein (uL-FABP) improves accuracy of MELD score to predict short-term mortality in patients with decompensated cirrhosis
Authors: Adria Juanola, Isabel Graupera, Salvatore Piano, Chiara Elia, Patricia Huelin, Cristina Solé, Octavi Bassegoda, Marta Carol, Gloria De Prada, Núria Fabrellas, Marta Cervera, Martina Perez, Laura Napoleone, Martin Bonacci, Elisa Pose, Elsa Solà, Pere Ginès
Journal: Journal of Hepatology (2019)
TCTAP C-180 Direct Stent Puncture Technique for Intraluminal Stent Recanalization in the Superficial Femoral and Popliteal Arteries In-stent Occlusion
Authors: Nai-Yu Chi, Po-Chao Hsu, Tsung-Hsien Lin, Ho-Ming Su, Wen-Chol Voon
Journal: Journal of the American College of Cardiology (2019)